An exploratory clinical study of β-glucan combined with camrelizumab and SOX chemotherapy as first-line treatment for advanced gastric adenocarcinoma

Backgroundβ-glucan has been reported to be a potential natural immune modulator for tumor growth inhibition. We aimed to evaluate the efficacy and safety of β-glucan plus immunotherapy and chemotherapy in the first-line treatment of advanced gastric adenocarcinoma.MethodsThis is a phase IB, prospect...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Yunqian Chu, Xuan He, Ya Xue, Hua Jiang, Chan Zhu, Chunjian Qi, Xing Zhang, Dongsheng Chen, Hanjue Dai, Qingying Xian, Wenyu Zhu
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2024-08-01
coleção:	Frontiers in Immunology
Assuntos:	β-glucan camrelizumab chemotherapy first-line gastric cancer
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1448485/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!